{"product_id":"mplt-ansoff-analysis","title":"(MPLT) MapLight Therapeutics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis MapLight Therapeutics, Inc. Ansoff Matrix Analysis helps you quickly understand the company’s growth options across market penetration, market development, product development, and diversification in a concise, actionable format. The page already includes a real preview\/sample of the analysis so you can assess style and substance before buying—purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eML-007C-MA in schizophrenia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eML-007C-MA is a fixed-dose M1\/M4 muscarinic agonist that MapLight Therapeutics is advancing in schizophrenia, keeping the company focused on a core CNS segment. Schizophrenia affects about 24 million people worldwide, so even small share gains can matter in a large, entrenched market.\u003c\/p\u003e\n\u003cp\u003eThis is a market penetration play, not a new-market bet: MapLight is aiming to win patients inside an existing indication with a differentiated mechanism. As a private company, MapLight does not disclose 2025 revenue, so the key value driver is clinical uptake rather than near-term sales scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eML-007C-MA in Alzheimer’s disease psychosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eML-007C-MA in Alzheimer’s disease psychosis lets MapLight Therapeutics, Inc. reuse one CNS asset in a second psychosis setting, deepening focus inside a narrow neuropsychiatry niche. Alzheimer’s affects about 6.9 million Americans age 65+ in 2024, and psychosis appears in roughly 30% to 50% of cases, so the addressable need is large. That gives the program a clear path to stronger penetration within an already targeted CNS footprint.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSevere CNS disorder focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc. says it is dedicated to severe central nervous system disorders; WHO estimates neurological conditions affect about 3.4 billion people worldwide. By staying in one broad CNS domain, it can reuse trial know-how, clinician ties, and safety data across related patient groups. That tight focus can raise market penetration in one niche before moving to adjacent CNS uses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFour-program pipeline concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc. shows tight market penetration: 4 of its 4 disclosed programs—ML-007C-MA, ML-004, ML-021, and ML-009—target CNS conditions. That means 100% of the pipeline stays inside one core therapeutic arena, not a spread into new categories. The strategy deepens know-how, but it also keeps the company exposed to one market set and one risk pool.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 programs, all CNS-focused\u003c\/li\u003e\n\u003cli\u003e100% pipeline concentration\u003c\/li\u003e\n\u003cli\u003eDeeper focus, not diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeural-circuit platform reuse\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc. can reuse its neural-circuit platform across existing CNS programs to keep target ID, assay design, and dose logic consistent. That is market penetration: it deepens use of the same scientific base instead of moving into a new domain. For a private CNS developer, this can cut repeat work and make program execution cleaner and faster.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReuse the same circuit-mapping core\u003c\/li\u003e\n\u003cli\u003eImprove consistency across CNS assets\u003c\/li\u003e\n\u003cli\u003eReduce duplicate early-stage work\u003c\/li\u003e\n\u003cli\u003eIntensify use of current capability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMapLight Bets on CNS Depth to Win Share in Schizophrenia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc. is using market penetration by pushing ML-007C-MA and other CNS programs deeper into schizophrenia and related psychosis markets, not into new categories. With 4 of 4 disclosed assets in CNS and schizophrenia affecting about 24 million people worldwide, the strategy is focused on share gain inside a large, familiar base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS-focused programs\u003c\/td\u003e\n\u003ctd\u003e4 of 4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline concentration\u003c\/td\u003e\n\u003ctd\u003e100%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSchizophrenia prevalence\u003c\/td\u003e\n\u003ctd\u003e~24 million worldwide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlzheimer's psychosis rate\u003c\/td\u003e\n\u003ctd\u003e~30% to 50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes MapLight Therapeutics, Inc.’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Ansoff Matrix view for MapLight Therapeutics to simplify growth strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, vetted source list linking each Ansoff growth pathway for MapLight Therapeutics to traceable, reputable references for faster due diligence and defensible strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eML-007C-MA schizophrenia to Alzheimer’s psychosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eML-007C-MA fits market development: the same asset is being moved from schizophrenia into Alzheimer’s disease psychosis, expanding the patient pool without changing the product. Schizophrenia affects about 24 million people worldwide, while Alzheimer’s disease affects about 55 million; psychosis in Alzheimer’s is common enough to create a new, large use case.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eML-004 autism spectrum disorder entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eML-004’s autism spectrum disorder work gives MapLight Therapeutics, Inc. a clear market-development step: it is moving an existing CNS asset into a new patient group for social communication deficits and irritability. Autism is a separate CNS market from schizophrenia and Parkinson’s disease, with the CDC estimating 1 in 36 8-year-olds identified with ASD. That expands MapLight’s reach into a large, underserved clinical segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eML-021 Parkinson’s disease entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eML-021 aims at the motor impairments that drive Parkinson’s disease care, opening MapLight Therapeutics, Inc. to a new, established CNS market. Parkinson’s affects nearly 10 million people worldwide and more than 1 million people in the United States, so the entry expands the company’s addressable patient pool. It also moves MapLight’s CNS science into a second disease area, which can widen partnering and revenue options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eML-009 agitation-related conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eML-009’s work on hyperactivity, impulsivity, and agitation points to a wider neuropsychiatric market than MapLight Therapeutics, Inc.'s lead psychosis program. Agitation affects many CNS settings, and the global antipsychotic market was about $17B in 2025, showing the size of adjacent demand.\u003c\/p\u003e\n\u003cp\u003eThis fits Ansoff market development: one asset, more patient groups. If ML-009 can show clean symptom control, it could reach ADHD, autism-related irritability, and dementia-related agitation use cases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader CNS reach\u003c\/li\u003e\n\u003cli\u003eHigher addressable patient pool\u003c\/li\u003e\n\u003cli\u003eLess dependence on psychosis alone\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMultiple adjacent CNS segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMapLight Therapeutics is targeting five distinct CNS segments: schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, Parkinson’s disease, and agitation-related conditions. That is an adjacent-market move, not a single-disease bet, because each indication has its own patients, prescribers, and trial path. Schizophrenia affects about 24 million people worldwide, and Alzheimer’s disease is the most common dementia, with over 55 million people living with dementia globally.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFive CNS segments\u003c\/li\u003e\n\u003cli\u003eAdjacency, not core reuse\u003c\/li\u003e\n\u003cli\u003eBroadens shot at approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMapLight Expands CNS Assets Into Major New Patient Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc. is using market development by taking the same CNS assets into new disease groups, mainly schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, Parkinson’s disease, and agitation-linked conditions.\u003c\/p\u003e\n\u003cp\u003eThat widens the patient base fast: schizophrenia affects about 24 million people worldwide, dementia about 55 million, and Parkinson’s nearly 10 million.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eML-007C-MA\u003c\/td\u003e\n\u003ctd\u003eAlzheimer’s psychosis\u003c\/td\u003e\n\u003ctd\u003eSame asset, new use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eML-004\u003c\/td\u003e\n\u003ctd\u003eASD\u003c\/td\u003e\n\u003ctd\u003eNew patient group\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eML-021\u003c\/td\u003e\n\u003ctd\u003eParkinson’s\u003c\/td\u003e\n\u003ctd\u003eNew CNS segment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMapLight Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality; the preview below is taken directly from the full report and the complete, editable Ansoff Matrix becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eML-007C-MA fixed-dose combination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eML-007C-MA is a fixed-dose combination of an M1\/M4 muscarinic agonist and one of MapLight Therapeutics, Inc.'s lead CNS assets. In Ansoff Matrix terms, this is product development: a new therapeutic candidate for an existing central nervous system market. As of 2025\/2026, MapLight has not disclosed product revenue from ML-007C-MA, so value is still pipeline-driven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eML-004 autism candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eML-004 is a separate autism spectrum disorder candidate, so MapLight Therapeutics, Inc. is adding a new asset rather than extending an existing commercial drug. That fits Ansoff Matrix product development: new product, existing CNS market base. With ASD affecting about 1 in 36 U.S. children, ML-004 targets a large and still under-served category.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eML-021 Parkinson’s candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eML-021 is MapLight Therapeutics, Inc.’s Parkinson’s candidate aimed at motor impairments, a major need in a disease that affects about 10 million people worldwide. It adds a distinct program to MapLight Therapeutics, Inc.’s CNS pipeline and broadens the company’s development-stage menu beyond its other neurology assets. In Ansoff terms, this is product development: a new therapy for an existing CNS market. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eML-009 GPCR52 PAM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eML-009 is a G-protein-coupled receptor 52 positive allosteric modulator, so it adds a new mechanism to MapLight Therapeutics, Inc.'s neuroscience pipeline. In Ansoff terms, this is product development: a new product for an existing market focus, not a move outside CNS. That mix can widen target coverage while keeping R\u0026amp;D aligned to one disease area.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew pharmacology: GPCR52 PAM\u003c\/li\u003e\n\u003cli\u003eSupports neuroscience-only strategy\u003c\/li\u003e\n\u003cli\u003eDiversifies pipeline risk\u003c\/li\u003e\n\u003cli\u003eFits product development in Ansoff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProprietary circuit-modulation platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc.'s proprietary circuit-modulation platform maps disease-linked neural circuits and tunes them with precision, so one core engine can generate multiple CNS candidates. In Ansoff terms, that is product development: new products, same target markets. WHO says neurological conditions affect over 3 billion people worldwide, underscoring the scale of the CNS demand pool.\u003c\/p\u003e\n\u003cp\u003eFor MapLight Therapeutics, Inc., the key advantage is repeatability: the platform can keep producing differentiated programs without changing the core market focus. That lowers discovery risk versus one-off assets and can support faster pipeline expansion, which matters in CNS where clinical failure rates stay high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame CNS markets, new product launches\u003c\/li\u003e\n\u003cli\u003ePrecision circuit targeting drives pipeline breadth\u003c\/li\u003e\n\u003cli\u003e3+ billion global neurological patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMapLight’s Product Development Push Targets Huge CNS Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc.'s Product Development moves use new CNS assets for the same neurology market, which matches Ansoff Matrix product development. ML-007C-MA, ML-004, ML-021, and ML-009 each add a new program or mechanism, while 2025\/2026 data still show no product revenue. The approach targets large unmet need, including 3 billion+ people with neurological conditions worldwide.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eML-007C-MA\u003c\/td\u003e\n\u003ctd\u003eNew CNS product\u003c\/td\u003e\n\u003ctd\u003eNo revenue disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eML-021\u003c\/td\u003e\n\u003ctd\u003eNew Parkinson's asset\u003c\/td\u003e\n\u003ctd\u003e10 million affected worldwide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFour candidates, multiple indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc. has four candidates spread across five CNS uses: schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, Parkinson’s disease, and agitation-related symptoms. That is portfolio diversification at both the product and market level, because it reduces reliance on one drug or one disease. With 4 assets and 5 indications, MapLight is building breadth before any single program fully de-risks the platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistinct mechanism classes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMapLight Therapeutics uses 2 distinct mechanism classes: ML-007C-MA is an M1\/M4 muscarinic agonist, while ML-009 is a GPCR52 positive allosteric modulator. That split lowers reliance on one modality and broadens pipeline risk. In Ansoff terms, it is related diversification inside the same CNS platform, not a single-bet strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePsychosis, autism, Parkinson’s, agitation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc. is not tied to one disorder or one symptom set; its programs span psychosis, social communication deficits, irritability, motor impairment, hyperactivity, impulsivity, and agitation. That breadth points to a diversification move in the Ansoff Matrix: new products aimed at several new clinical markets. In 2025-2026, this matters because CNS drug development can spread risk across multiple high-need patient groups, not just one indication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlatform plus pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc. uses a proprietary neural-circuit platform plus multiple pipeline assets, so diversification is built in. The platform can surface new therapeutic targets beyond one disease area, which lowers single-asset risk and broadens the company’s Ansoff Matrix profile toward product and market expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform creates repeatable target discovery\u003c\/li\u003e\n\u003cli\u003ePipeline reduces reliance on one asset\u003c\/li\u003e\n\u003cli\u003eBroader indication reach supports growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRedwood City biotech base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc. was founded in 2018, renamed in August 2019, and is based in Redwood City, California. That young, Bay Area base fits a diversification play in CNS, where one platform can support multiple assets instead of a single-drug profile. In ansoff terms, this points more to product development and diversification than simple market penetration.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFounded: 2018\u003c\/li\u003e\n\u003cli\u003eRenamed: August 2019\u003c\/li\u003e\n\u003cli\u003eBase: Redwood City, California\u003c\/li\u003e\n\u003cli\u003eModel: multi-asset CNS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMapLight’s Multi-Asset CNS Pipeline Spreads Risk and Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMapLight Therapeutics, Inc. shows diversification in Ansoff terms through 4 pipeline assets across 5 CNS indications, reducing dependence on any single drug or market. Its 2 mechanism classes, M1\/M4 agonist and GPCR52 PAM, spread scientific risk and widen future option value. This is related diversification, not a single-asset bet.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssets\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndications\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMechanism classes\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFounded\u003c\/td\u003e\n\u003ctd\u003e2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234677596425,"sku":"mplt-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mplt-ansoff-matrix.webp?v=1785725420","url":"https:\/\/dcfanalyst.com\/products\/mplt-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}